Omidria receives FDA approval for use in cataract surgery, IOL replacement

June 3, 2014

The U.S. Food and Drug Administration has approved Omeros’ phenylephrine and ketorolac injection, Omidria, for use during cataract surgery and intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain.

Seattle-The U.S. Food and Drug Administration has approved Omeros’ phenylephrine and ketorolac injection, Omidria, for use during cataract surgery and intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain. 

According to Omeros, Omdria is a proprietary combination of mydriatic agent and an anti-inflammatory agent that is added to irrigation solution used during cataract surgery and other IOL replacement procedures.

“Omidria is an important advance in cataract and lens replacement surgery,” says Richard L. Lindstrom, MD, adjunct clinical professor emeritus at the University of Minnesota’s Department of Ophthalmology and past president of both the American Society of Cataract and Refractive Surgeons and the International Society of Refractive Surgery. “Miosis and postoperative pain are frequent and largely unpredictable, and their occurrence can make the procedure more difficult for the surgeon and unpleasant postoperatively for the patient. While not changing their surgical routine, the use of Omidria will better allow ophthalmic surgeons to control the operative experience and, I expect, will improve surgical outcomes.”

Related Content:

News | Cataract Surgery | Cataract